ArticlePloS one2025
Spinal cord lesions in relapsing-remitting multiple sclerosis: Prognostic value of intrathecal production of immunoglobulins.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundControversy exists about the radiological follow-up of the spinal cord in MS, since cord lesions are mostly symptomatic, but there are also reports that 10% - 25% are asymptomatic. Therefore, a need exists for biomarkers to identify patients prone to future cord involvement where routine cord imaging at follow-up is warranted. Elevated intrathecal IgM has been shown to be cross-sectionally associated with more cord lesions. This study investigated whether there also is a longitudinal relation.
methodsRelapse-onset MS patients with baseline CSF and spinal MRI available were retrospectively identified. Cross-sectional associations between intrathecal immunoglobulin production and cord lesions were assessed. For the subgroup where follow-up spinal MRIs were available, Andersen-Gill time-to-event models were used to estimate the risk of new cord lesions based on CSF makers and important covariates.
results394 patients had baseline CSF and cord imaging available, of which 253 had CSF and serum IgG data available, 139 IgM data and 138 both IgG and IgM data. At baseline, patients with intrathecal IgG (IgG IF+; 175 out of 253) and IgM production (IgM IF+; 44 out of 139) had more cord lesions (IgG IF+, mean 1.30 vs. 0.85 spinal cord lesions, p < 0.01; IgM IF+ mean 1.64 vs. 0.91 spinal cord lesions, p < 0.05). After correction for important covariates, only IgM IF+ (IgM IF+ β = 0.53, p = 0.02; IgG IF+ β = 0.38, p = 0.13) was a statistically significant positive predictor for more spinal cord lesions at baseline. For 66 patients follow-up cord imaging was available with a median follow-up time of 2 years (IQR 1.1-4.2). Longitudinally, there was no statistically significant association of IgM and IgG IF+ with new future cord lesions.
conclusionWhile intrathecal IgM production is cross-sectionally independently associated with spinal cord lesions, this study does not support a role for predicting new cord lesions at follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.